Several brokerages have updated their recommendations and price targets on shares of HCA Healthcare (NYSE: HCA) in the last few weeks:
- 7/15/2026 – HCA Healthcare had its “market perform” rating reaffirmed by Sanford C. Bernstein.
- 7/15/2026 – HCA Healthcare was given a new $435.00 price target by Royal Bank Of Canada.
- 7/14/2026 – HCA Healthcare was given a new $450.00 price target by Jefferies Financial Group Inc..
- 7/14/2026 – HCA Healthcare had its price target lowered by KeyCorp from $510.00 to $475.00. They now have an “overweight” rating on the stock.
- 7/13/2026 – HCA Healthcare had its price target lowered by Wells Fargo & Company from $436.00 to $428.00. They now have an “equal weight” rating on the stock.
- 7/8/2026 – HCA Healthcare was downgraded by Barclays PLC from “overweight” to “equal weight”. They now have a $427.00 price target on the stock, down from $496.00.
- 7/8/2026 – HCA Healthcare had its “equal weight” rating reaffirmed by Barclays PLC. They now have a $427.00 price target on the stock, down from $496.00.
- 7/7/2026 – HCA Healthcare was given a new $528.00 price target by Raymond James Financial, Inc..
- 7/7/2026 – HCA Healthcare had its price target lowered by Cantor Fitzgerald from $588.00 to $525.00. They now have an “overweight” rating on the stock.
- 7/1/2026 – HCA Healthcare had its “overweight” rating reaffirmed by Cantor Fitzgerald.
- 6/22/2026 – HCA Healthcare had its price target lowered by TD Cowen from $500.00 to $431.00. They now have a “buy” rating on the stock.
- 6/9/2026 – HCA Healthcare was downgraded by Weiss Ratings from “buy (b-)” to “hold (c+)”.
- 6/4/2026 – HCA Healthcare was given a new $413.00 price target by Truist Financial Corporation.
- 6/4/2026 – HCA Healthcare had its price target lowered by Sanford C. Bernstein from $503.00 to $413.00. They now have a “market perform” rating on the stock.
- 6/4/2026 – HCA Healthcare had its price target lowered by Sanford C. Bernstein from $503.00 to $413.00. They now have a “market perform” rating on the stock.
- 5/19/2026 – HCA Healthcare had its price target lowered by JPMorgan Chase & Co. from $535.00 to $490.00. They now have a “neutral” rating on the stock.
- 5/18/2026 – HCA Healthcare was downgraded by Weiss Ratings from “buy (b)” to “buy (b-)”.
HCA Healthcare Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 16th were paid a dividend of $0.78 per share. This represents a $3.12 annualized dividend and a yield of 0.8%. The ex-dividend date of this dividend was Tuesday, June 16th. HCA Healthcare’s payout ratio is presently 10.73%.
The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.
Featured Stories
- Five stocks we like better than HCA Healthcare
- Alphabet’s AI Spending Question Looms Over Q2 Earnings
- 3 Small-Cap Stocks Trading Under $10 With Room to Run
- CleanSpark Inks a $6.6B AI Lease to Become a Digital Landlord
- 3 Gold Stocks Under $5 With Massive Upside
Receive News & Ratings for HCA Healthcare Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare Inc and related companies with MarketBeat.com's FREE daily email newsletter.
